10-Q: BioCardia Reports Q2 2024 Results, Focuses on Clinical Trial Progress and Funding

BioCardia's Q2 2024 report highlights a decrease in operating expenses and ongoing clinical trial advancements, while also noting substantial doubt about the company's ability to continue as a going concern without additional funding.

Summary

• BioCardia, a clinical-stage company, reported its financial results for the second quarter of 2024, showing a net loss of $1.646 million, or $0.88 per share, compared to a net loss of $3.424 million, or $2.52 per share, for the same period in 2023.
• The company's revenue decreased to $3,000 in Q2 2024 from $43,000 in Q2 2023, and to $58,000 for the six months ended June 30, 2024, from $107,000 for the same period in 2023.
• Research and development expenses decreased to $800,000 in Q2 2024 from $2.314 million in Q2 2023, and to $2.041 million for the six months ended June 30, 2024, from $4.698 million for the same period in 2023, primarily due to clinical staff reductions.
• Selling, general, and administrative expenses also decreased to $852,000 in Q2 2024 from $1.181 million in Q2 2023, and to $1.941 million for the six months ended June 30, 2024, from $2.371 million for the same period in 2023, due to personnel realignment.
• The company had cash and cash equivalents of $1.421 million as of June 30, 2024, and management believes this is not sufficient to fund operations through September 2024.
• BioCardia is actively advancing its CardiAMP autologous cell therapy and CardiALLO allogeneic cell therapy platforms through ongoing clinical trials.
• The company is also developing its Helix biotherapeutic delivery system and has entered into partnerships with StemCardia and CellProthera.
• A 1-for-15 reverse stock split was effected on May 30, 2024, and the authorized common shares were reduced from 100,000,000 to 50,000,000.
• BioCardia is seeking additional capital through various means, including potential equity and debt arrangements, to fund its operations and meet its obligations.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and partnerships, the significant financial challenges and going concern warning weigh heavily on the overall sentiment. The company's need for additional funding and the risk of delisting from Nasdaq are major concerns.

Positives

• The company's net loss per share improved year-over-year.
• Operating expenses, including research and development and selling, general, and administrative costs, decreased significantly.
• BioCardia is actively progressing its clinical trials for its cell therapy platforms.
• The company has secured partnerships for its biotherapeutic delivery system.
• BioCardia has received FDA market clearance for its Morph DNA platform and is expanding its product line.
• The company has raised additional capital through the sale of common stock and warrants.

Negatives

• The company's revenue decreased significantly compared to the same period last year.
• BioCardia has incurred net losses and negative cash flows since its inception.
• The company's cash and cash equivalents are not sufficient to fund operations through September 2024.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company is dependent on raising additional capital to fund its operations and clinical trials.
• The company is not in compliance with Nasdaq listing requirements.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is a risk that the company may not be able to raise sufficient funds on acceptable terms.
• Failure to raise additional capital may require the company to reduce operating expenses, delay product development, or cease operations.
• The company is subject to the risks associated with clinical trials and regulatory approvals.
• The company's stock is subject to delisting from the Nasdaq if it does not regain compliance with listing requirements.
• The company's future revenue is uncertain and dependent on the success of its clinical trials and commercialization efforts.
• The company may experience dilution of existing stockholders if it raises additional capital through the sale of equity.

Future Outlook

The company plans to raise additional capital to fund its operations and continue the development of its therapeutic candidates. BioCardia expects to complete follow-up in the CardiAMP HF trial and prepare the dataset for potential submission to Japan PMDA and the FDA. The company also expects to complete enrollment in the CardiAMP Cell Therapy Heart Failure II Trial two years after the first patient is randomized.

Management Comments

• Management believes that the cash and cash equivalents of approximately $1.4 million as of June 30, 2024 are not sufficient to fund planned expenditures and meet obligations through September 2024.
• Management plans to raise additional capital, potentially including non-dilutive collaboration and licensing arrangements, debt or equity financing, or a combination from these sources.
• Management believes in the viability of its strategy to raise additional funds, but there can be no assurances that it will be able to obtain additional capital on acceptable terms.

Industry Context

BioCardia is operating in the competitive field of regenerative medicine, focusing on cell therapies for cardiovascular and pulmonary diseases. The company's partnerships and focus on its Helix delivery system are aimed at differentiating it from competitors. The company's financial challenges highlight the capital-intensive nature of the biotechnology industry, particularly for clinical-stage companies.

Comparison to Industry Standards

• BioCardia's revenue is significantly lower than many commercial-stage biotech companies, reflecting its focus on clinical development.
• The company's operating expenses are typical for a clinical-stage biotech company, but the decrease in expenses reflects cost-cutting measures.
• The company's cash position is weak compared to industry standards, raising concerns about its ability to fund ongoing operations and clinical trials.
• The company's reliance on external funding is common for clinical-stage biotech companies, but the uncertainty about its ability to raise additional capital is a significant risk.
• The company's clinical trial progress is comparable to other companies in the regenerative medicine space, but the outcomes of these trials will be critical for its future success.
• The company's partnerships and focus on its Helix delivery system are a potential differentiator, but the success of these initiatives is yet to be determined.

Related Party Transactions

• The company recorded a related party payable for discounts owed to BSLF, L.L.C. in accrued expenses and other current liabilities of $42,000 as of June 30, 2024.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital.
• Employees may be affected by potential cost-cutting measures or delays in product development.
• Customers and partners may be impacted by the company's financial instability and potential delays in product development.
• Creditors face the risk of non-payment if the company is unable to raise sufficient capital.

Next Steps

• Complete follow-up in the CardiAMP HF trial and prepare the dataset for potential submission to Japan PMDA and the FDA.
• Continue enrollment in the CardiAMP Cell Therapy Heart Failure II Trial.
• Continue development of the CardiALLO allogeneic cell therapy trial in heart failure.
• Seek FDA clearance for the Morph-DNA product family.
• Raise additional capital to fund operations and clinical trials.
• Maintain compliance with Nasdaq listing requirements.

Key Dates

Keywords

BioCardia, Cell Therapy, CardiAMP, CardiALLO, Clinical Trials, Heart Failure, Myocardial Ischemia, Biotherapeutic Delivery, Helix, Reverse Stock Split, Funding, Financial Results, Morph DNA, FDA Clearance